TOVX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. TOVX is in a clear bearish trend with weakening momentum (negative, expanding MACD histogram) and no near-term catalysts (no recent news, no notable hedge/insider activity, no congress trades). For an impatient buyer, the setup does not offer an attractive risk/reward until it either reclaims key resistance (~0.191–0.208) or shows a confirmed reversal off support.
Price/Trend: Regular session -3.49% with a small post-market uptick (+0.33%)—overall weak tape. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), confirming a downtrend.
Momentum: MACD histogram is negative (-0.00112) and negatively expanding, signaling increasing downside momentum.
RSI: RSI_6 at 31.7 is near oversold but still labeled neutral here—this can precede bounces, but it is not a confirmed reversal signal.
Levels: Support S1 ~0.174 (then S2 ~0.164). Resistance/pivot ~0.191, then R1 ~0.208 and R2 ~0.219. Current price (0.1806) is closer to support than resistance, meaning downside risk to 0.174/0.164 remains meaningful if selling continues.
Pattern/Probability: Similar-pattern stats imply mild upside next day/week but a negative 1-month bias (-4.75%), aligning with the broader bearish trend.
Intellectia Proprietary Trading Signals
RSI near oversold levels can allow for short-lived technical bounces, especially if 0.174 support holds.
No heavy negative macro backdrop today (S&P 500 -0.14%)—market not in a broad selloff.
Post-market slightly green (+0.33%), but this is not a confirmed reversal.
and deteriorating MACD momentum.
Latest reported quarter: 2025/Q3. Revenue was 0 (no improvement). Net loss widened to -$4.361M (down -43.55% YoY). EPS fell to -0.45 (down -93.39% YoY). Overall, the quarter shows deteriorating profitability with no revenue growth, which weakens fundamental support for a near-term rally.
No analyst rating or price target change data was provided, so there is no visible Wall Street-driven bullish/bearish consensus shift to rely on. Pros (in theory): biotech names can move sharply on catalysts. Cons (based on available data): no current catalysts, worsening quarterly losses, and a confirmed bearish technical trend.
